Key Findings:  THCv (CB1 neutral antagonist) may provide a therapeutic treatment option for obesity, where functional connectivity is altered in certain regions of the brain.
Type of Study:  Double Blind Clinical Trial
Study Sample Size:  20
Study Result:  Positive
Study Location(s):  United Kingdom
Year of Pub:  2016
Cannabinoids Studied:  Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source:  Unspecified
Receptors Studied:  CB1